ValiRx' cancer drug shows positive in vivo data

ValiRx, a UK cancer therapeutics and diagnostics company, has completed its first collaborative stage with Cancer Research Technology. Trials  completed under the collaborative agreement with the charity-funded  research group have shown positive in vivo results for its therapeutic  cancer compound, VAL 101, according to the firm.

Data from the studies indicated tumor growth reduction was dose  dependent with no unexpected side effects, indicating that the gene  silencing drug is well tolerated within the effective dose range.

The study also identified a potential suitable delivery system for the  compound. ValiRx has now obtained completed in vivo data from CRT and,  based on these successful results, ValiRx will progress to late stage in  vivo preclinical studies for VAL 101. The London-based company says it  is continuing with its plans to progress VAL 101 towards Phase I  filing.